Sera Prognostics (NASDAQ: SERA) PRIME study results published in journal

Rhea-AI Filing Summary

Sera Prognostics, Inc. filed a current report to highlight a communication event rather than a financial update. On January 7, 2026, the company issued a press release announcing publication of the results of its Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study in the Pregnancy Journal.

The newly published PRIME study results are scheduled to be discussed during a Jefferies-hosted fireside chat on January 9, 2026, at 8:30 am ET. The press release is furnished as Exhibit 99.1 and, along with the related disclosure under Item 7.01, is treated as "furnished" rather than "filed" for liability purposes under the Exchange Act.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000153496900015349692026-01-072026-01-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 07, 2026

Sera Prognostics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40606	26-1911522
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2749 East Parleys Way Suite 200
Salt Lake City, Utah				84109
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (801) 990-0520

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share		SERA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 7, 2026, Sera Prognostics, Inc. (the “Company”) issued a press release announcing publication of the results of the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (“PRIME”) study in the Pregnancy Journal (available at https://obgyn.onlinelibrary.wiley.com/doi/10.1002/pmf2.70202). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. These newly published PRIME study results are scheduled to be discussed during a fireside chat hosted by Jefferies on January 9, 2026, at 8:30 am ET.

The information contained in Item 7.01, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or into any filing or other document pursuant to the Exchange Act, except to the extent required by applicable law or regulation.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press release dated January 7, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			SERA PROGNOSTICS, INC.
Date:	January 7, 2026	By:	/s/ Austin Aerts
			Austin Aerts Chief Financial Officer

FAQ

What did Sera Prognostics (SERA) report in this 8-K filing?

The company reported that it issued a press release on January 7, 2026 announcing publication of the results of its PRIME study in the Pregnancy Journal and furnished that release as Exhibit 99.1.

Where were the Sera Prognostics PRIME study results published?

The PRIME study results were published in the Pregnancy Journal, with the article available through the journal’s online platform at the URL cited by Sera Prognostics.

What is the PRIME study mentioned by Sera Prognostics (SERA)?

PRIME stands for Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs, a study whose results Sera Prognostics highlighted as newly published in the Pregnancy Journal.

Will Sera Prognostics discuss the PRIME study results with investors?

Yes. The filing notes that the newly published PRIME study results are scheduled to be discussed during a fireside chat hosted by Jefferies on January 9, 2026, at 8:30 am ET.

How is the press release treated under U.S. securities laws in this Sera Prognostics 8-K?

The information in Item 7.01 and Exhibit 99.1 is deemed "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, limiting its treatment under certain liability provisions.

What exhibits are included with this Sera Prognostics (SERA) 8-K?

The filing lists Exhibit 99.1 as a press release dated January 7, 2026 and Exhibit 104 as the cover page interactive data file embedded within the Inline XBRL document.